Aerie Pharmaceuticals
Innovative ophthalmic therapies for glaucoma, dry eye, and retinal diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $770m Valuation: $770m 5.6x EV/Revenue -12.1x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 187 % | 20 % | 134 % | (22 %) | 40 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (704 %) | (180 %) | (131 %) | (51 %) | (46 %) | (13 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (971 %) | (290 %) | (220 %) | (38 %) | (66 %) | (9 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 344 % | 115 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Aerie Pharmaceuticals is a prominent player in the ophthalmic pharmaceuticals sector, focusing on the research and development (R&D) of innovative treatments for eye diseases. The company primarily targets patients suffering from glaucoma, dry eye, retinal diseases, and other ocular conditions. By concentrating on these specific ailments, Aerie aims to address significant unmet medical needs in the eye care market.
Aerie operates in the pharmaceutical industry, specifically within the niche of ophthalmology. This market includes a wide range of stakeholders such as healthcare providers, eye care specialists, and patients who require advanced treatments for their eye conditions. The company’s business model revolves around discovering, developing, and commercializing first-in-class therapies. "First-in-class" means that these therapies are the first of their kind to be developed and brought to market, offering new treatment options where none previously existed.
Revenue generation for Aerie Pharmaceuticals comes from the sale of its approved products. The company invests heavily in R&D to create new drugs, which are then subjected to rigorous clinical trials. Once these drugs receive regulatory approval, they are marketed and sold to healthcare providers and pharmacies, who then distribute them to patients. This process ensures a steady stream of income as long as the products remain effective and in demand.
Aerie’s financial performance is closely monitored by investors, as evidenced by its stock being publicly traded on NASDAQ under the ticker symbol AERI. The company’s stock performance, including daily and yearly highs and lows, reflects investor confidence and market conditions.
In summary, Aerie Pharmaceuticals is dedicated to advancing eye care through innovative drug development, serving a specialized market with significant medical needs. The company’s focus on first-in-class therapies positions it as a leader in the ophthalmic pharmaceutical industry.
Keywords: ophthalmic, pharmaceuticals, glaucoma, dry eye, retinal diseases, R&D, first-in-class, therapies, NASDAQ, AERI.